Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06692764 · ClinicalTrials.gov registry record · Phase 2

A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure

A Phase 2 study of Atherosclerotic Cardiovascular Disease, sponsored by AstraZeneca.

Completed
Registry status
Phase 2
Development phase
202
Enrollment target
20
Study locations

NCT06692764 is a Phase 2 study of Atherosclerotic Cardiovascular Disease that has completed, run by AstraZeneca. The registered enrollment target is 202 participants, below the 7,558-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06692764, a Phase 2 study of Atherosclerotic Cardiovascular Disease, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 2
Development phase
202 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase II, multi-centre, randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of AZD0780 Dose 1 versus placebo on systolic blood pressure (SBP) at Week 4, as measured by 24-hour ambulatory blood pressure monitoring (ABPM) in participants with ASCVD or risk equivalents and LDL-C ≥ 70 mg/dL, on stable medication.

Conditions Studied

Atherosclerotic Cardiovascular Disease

Interventions

  • DRUG Placebo
  • DRUG AZD0780

Study Locations (20)

Florida

  • Research Site - Boca Raton
  • Research Site - Hialeah
  • Research Site - Jacksonville
  • Research Site - Miami
  • Research Site - Miami
  • Research Site - Miami
  • Research Site - Miami
  • Research Site - Ocala
  • Research Site - Port Orange
  • Research Site - Tamarac

California

  • Research Site - Inglewood
  • Research Site - Northridge
  • Research Site - Pomona

Illinois

  • Research Site - Chicago

Maryland

  • Research Site - Potomac

Massachusetts

  • Research Site - New Bedford

New York

  • Research Site - New Windsor

Ohio

  • Research Site - Beavercreek

Pennsylvania

  • Research Site - Horsham

Trial Details

FieldValue
Enrollment Target 202 participants
Start Date 2024-10-30
Est. Completion 2025-05-02
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06692764

The ClinicalTrials.gov registry entry for NCT06692764 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,558-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (97% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atherosclerotic Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06692764 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT06692764 about?

NCT06692764 is a clinical study titled "A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure". This is a Phase II, multi-centre, randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of AZD0780 Dose 1 versus placebo on systolic blood pressure (SBP) at Week 4, as measured by 24-hour ambulatory blood pressure monitoring (ABPM) in participants with ASCVD or risk eq...

What is the current status of trial NCT06692764?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 202 participants. The study started on 2024-10-30. Estimated completion is 2025-05-02.

What conditions does trial NCT06692764 study?

This clinical trial studies the following conditions: Atherosclerotic Cardiovascular Disease.

What interventions are being tested in trial NCT06692764?

The interventions under investigation include: Placebo (DRUG), AZD0780 (DRUG).

Who is sponsoring clinical trial NCT06692764?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06692764 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atherosclerotic Cardiovascular Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atherosclerotic Cardiovascular Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.